

VORTRAG

Prof. Dr. Jonathan Kimmelman

Dept. of Equity, Ethics and Policy
McGill University, Canada

A Catalog of Moral Inefficiencies in Drug Development

Drug development is notoriously risky and failure prone: companies spend in excess of \$2 billion to bring a single drug to market. Less widely appreciated is that animals and patients that participate in research also bear a substantial amount of risk and burden in drug development, and much of this sacrifice is gratuitous. In this talk, I will present a map of drug development that surfaces its moral and scientific dimensions. I will further argue that researchers, regulators, medical centres and funders bear obligations to economize on the sacrifices animals and patients are asked to make in drug development. I will then use my moral map of drug development to describe three broad levels of moral inefficiency in drug development (and practices that tax moral efficiencies at each of these levels). The first level is experimental moral inefficiency (e.g. using more people and/or animals than necessary to resolve a medical hypothesis). The second is trajectory level moral inefficiency (e.g. using people and animals than necessary to determine whether to accept or reject a novel treatment). The third is program-level moral inefficiency (e.g. using more people and animals than needed to discover an effective strategy for a given condition). I will close by describing various practical and policy-level tools for reducing moral inefficiencies in drug development.

26. Juni 2024

16:00 – 17:30 Uhr

Seminarraum EGM (Humboldtallee 36)

Anmeldung für Online-Teilnahme unter jan.hinrichsen@med.uni-goettingen.de

In Kooperation mit



Aktuelle Informationen
www.egm.umg.eu

UNIVERSITÄTSMEDIZIN
GÖTTINGEN : **UMG**